Metformin Combined With Chemotherapy for Pancreatic Cancer

Exclusion Criteria

• •Clinical or radiological evidence of CNS metastases
• •Pregnancy (positive serum pregnancy test) and lactation
• •Serious concomitant systemic disorder that would compromise the safety of the patient, at the discretion of the investigator
• •Patients who have any severe and/or uncontrolled medical conditions:
• •* unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to randomization, serious uncontrolled cardiac arrhythmia
• •* uncontrolled diabetes as defined by fasting serum glucose \>2X ULN.
• •* active or uncontrolled severe infection.
• •* cirrhosis, chronic active hepatitis or chronic persistent hepatitis
• •* severely impaired lung function
• •Previous treatment with erlotinib
• •Previous treatment with gemcitabine for metastatic disease
• •Previous treatment with gemcitabine combined with radiotherapy for locally advanced pancreatic cancer within 6 months prior to study entry
• •Patients with a known hypersensitivity to metformin
• •Use of metformin in the previous 6 months